Retrophin

Martin Shkreli
Shkreli testifying before the House Committee on Oversight and Government Reform, 2016
Born	1982/1983 (age 33–34) Brooklyn, New York, U.S.
Nationality	American
Alma mater	Baruch College
Occupation	Corporate executive, hedge fund manager, entrepreneur, livestreamer
Known for	Turing Pharmaceuticals; Retrophin
Criminal charge	Securities fraud

Martin Shkreli (/ˈʃkrɛli/, born 1982 or 1983) is an American entrepreneur and pharmaceutical executive. He is co-founder of the hedge fund MSMB Capital Management, co-founder and former chief executive officer (CEO) of the biotechnology firm Retrophin, and founder and former CEO of Turing Pharmaceuticals.

In September 2015, Shkreli received widespread criticism when Turing obtained the manufacturing license for the antiparasitic drug Daraprim and raised its price by a factor of 56 (from US$13.5 to US$750 per pill), leading him to be referred to by media as "The Most Hated Man in America".

In December 2015, Shkreli was arrested by the FBI after being indicted on federal charges of securities fraud. He is free on bail pending trial.

He resigned as CEO of Turing Pharmaceuticals and was replaced by the company's board chairman, Ron Tilles.

In January 2016, Fortune estimated the then 32 year old Shkreli's net worth as at least US $45,000,000.

Shkreli was born in Coney Island Hospital, Brooklyn. He is the son of Albanian and Croatian immigrants who worked as janitors. He, his two sisters, and his brother grew up in a working class community in Sheepshead Bay, Brooklyn.